Biolegend, 317401, Purified anti-human CD4 Antibody, 25μg

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.
25μg
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: Chimpanzee
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human peripheral T cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested IHC-F - Verified
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunohistochemistry, a concentration range of 5.0 - 10 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454). In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9
Application References(PubMed link indicates BioLegend citation): Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36. Linder J, et al. 1987. Am. J. Pathol. 127:1. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC) Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen) Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations: Lu X, et al. 2021. J Exp Med. 218: . PubMed McIlwain DR, et al. 2021. Cell Host Microbe. 29:1828. PubMed Wang D, et al. 2022. Int J Oral Sci. 14:8. PubMed Feyaerts D, et al. 2022. Cell Rep Med. 3:100680. PubMed Gernoux G, et al. 2020. Mol Ther. 28:747. PubMed Brinkmann CR, et al. 2018. mSphere. 3:e00616. PubMed Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed Son YM, et al. 2020. Eur J Immunol. 50:1067. PubMed Gao H, et al. 2021. J Virol. :. PubMed Santos R, et al. 2017. Nat Commun. . 10.1038/s41467-017-01760-5. PubMed Volchenkov R, et al. 2017. Front Immunol. 0.818055556. PubMed Fletcher–Jones A, et al. 2019. Elife. 8:e44252. PubMed Delgobo M, et al. 2021. Front Immunol. 12:584538. PubMed Oberg HH, et al. 2020. J Leukoc Biol. 107:1081. PubMed Harshe RP, et al. 2020. Nat Commun. 11:5894. PubMed Li Y, et al. 2019. Front Immunol. 0.460416667. PubMed Bovay A, et al. 2020. Hum Vaccin Immunother. 16:3103. PubMed Ma F, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.10.011. PubMed Martins MA, et al. 2017. AIDS Res Hum Retroviruses. 33:843. PubMed Cobb DA, et al. 2022. J Immunother Cancer. 10:. PubMed Kong R, et al. 2019. Cell. 178:567. PubMed Martins M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006529. PubMed Perez MD, et al. 2020. Sci Rep. 10:15748. PubMed Wastyk HC, et al. 2021. Cell. 184(16):4137-4153.e14. PubMed Alsahafi N, et al. 2017. J Virol. 91:e00109. PubMed Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed Ardain A, et al. 2019. Nature. 570:528. PubMed Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed Cardoso V, et al. 2017. Nature. 549:277. PubMed Li G, et al. 2022. Mol Ther Oncolytics. 24:887. PubMed Majri SS, et al. 2018. J Immunol. 200:110. PubMed Matos TR, et al. 2017. J Clin Invest. 127:4031. PubMed Lou F, et al. 2020. Immunity. 53(1):204-216.e10. PubMed Yang J, et al. 2020. Nat Commun. 11:4402. PubMed Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed Martin E, et al. 2020. JCI Insight. :5. PubMed Seyfarth J, et al. 2018. Mol Cell Pediatr. 5:2. PubMed Prévost J, et al. 2018. Virology. 515:38:00. PubMed Gernoux G, et al. 2021. Mol Ther Methods Clin Dev. 20:660. PubMed Chiou SH, et al. 2021. Immunity. 54:586. PubMed
RRID: AB_571962 (BioLegend Cat. No. 317401) AB_571963 (BioLegend Cat. No. 317402)
Structure: Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution: T cell subset, majority of thymocytes, monocytes/macrophages
Function: MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor: MHC class II molecules, HIV gp120, IL-16
Cell Type: Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: 1. Center D, et al. 1996. Immunol. Today 17:476. 2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.
Gene ID: 920
UniProt: View information about CD4 on UniProt.org
Clone: OKT4
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: T4
Isotype: Mouse IgG2b, κ
Q: I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
A: TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.